BUSINESS
Daiichi Sankyo, AZ to Step Up Promotion for Nexium upon Lifting of Long-Term Prescription Ban
Daiichi Sankyo and AstraZeneca K.K. (AZ) will step up their copromotion efforts for the proton pump inhibitor (PPI) Nexium (esomeprazole) upon the lifting of its long-term prescription ban on October 1. By recommending the use of questionnaires to doctors, the…
To read the full story
BUSINESS
- Sumitomo Pharma Sees iPSC Therapy as Potential US$1 Billion Global Product
February 18, 2026
- AstraZeneca Launches Japan Registry Study of Imfinzi in Limited-Stage SCLC
February 18, 2026
- Asahi Kasei Gets Global Rights to Alchemedicine’s Lead Compounds
February 18, 2026
- Teijin, ASKA Hook Up on Gynecology Drug Discovery
February 18, 2026
- Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
February 17, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





